Market Overview

UPDATE: Morgan Stanley Reiterates Overweight Rating, Raises PT on ResMed

Share:
Related RMD
20 Biggest Mid-Day Gainers For Tuesday
Benzinga's Top Upgrades, Downgrades For January 24, 2017

In a report published Wednesday, Morgan Stanley reiterated its Overweight rating on ResMed (NYSE: RMD), and slightly raised its price target from $32.95 to $33.37.

Morgan Stanley noted, “While recovery in US device growth was observed, ROW device growth looked likely to continue deceleration from double-digit growth in FY11 to the low-single-digit growth reported in Q212 – the positive surprise of +7.0% in Q312 was impressive against the trend of ASP pressure in France and changes to PSG payment in Germany, and the stock is now priced for the positive level to continue.”

ResMed closed on Tuesday at $31.56.

Latest Ratings for RMD

DateFirmActionFromTo
Jan 2017JP MorganUpgradesNeutralOverweight
Sep 2016Bank of AmericaUpgradesNeutralBuy
Sep 2016JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for RMD
View the Latest Analyst Ratings

Posted-In: Morgan StanleyAnalyst Color Price Target Analyst Ratings

 

Related Articles (RMD)

View Comments and Join the Discussion!